NAŁÓG PALENIA PAPIEROSÓW KLASYCZNYCH I ELEKTRONICZNYCH A RYZYKO SKUTECZNEJ FARMAKOTERAPII

Paulina Brewczyńska, Justyna Makowska, Dorota Skrajnowska, Marta Teryks, Andrzej Tokarz

Bibliografia

1.      Kroon L.A. Drug interactions with smoking. Am. J. Health-Syst. Pharm. 2007, 64 (18), 1917-1921.

2.      Zevin S., Benowitz N.L. Drug interactions with tobacco smoking: an update. Clin. Pharmacokinetic. 1999, 36, 425-438.

3.      Kroon L.A. Drug interactions and smoking: raising awareness for acute and critical care providers. Crit. Care Nurs. Clin. North Am. 2006, 18, 53-62.

4.      Schaffer S.D., Yoon S., Zadezensky I. A review of smoking cessation: potentially risky effects on prescribed medications. J. Clin. Nurs. 2009, 18(11), 1533-1540.

5.      Stańczak A., Lewgowd W. Interakcje leków ze składnikami dymu tytoniowego Cz. II. Brom.  Chem. Toksykol. 2009, XLII (1), 97-103.

6.      Stańczak A., Lewgowd W. Interakcje leków ze składnikami dymu tytoniowego Cz. I. Brom. Chem. Toksykol. 2008, XLI (4), 1030-1036.

7.      Mańka M. Niepożądane reakcje lekowe u palaczy tytoniu. Puls Medycyny. 2012, 14(253) (www.kodekswalkizrakiem.pl/ download/pdf/20121022_Puls_Medycyny.pdf)

8.      Fankhauser M. Drug interactions with tobacco smoke: implications for patient care. Current Psychiatry, 2013, 12(1), 12-16.

9.      Komunikat z badań BS/107/2012; Postawy wobec palenia papierosów CBOS, Warszawa, sierpień 2012 (www.cbos.pl/ SPISKOM.POL/2012/K_107_12.PDF)

10.    Raport z ogólnopolskiego badania ankietowego na temat postaw wobec palenia tytoniu (pssekoszalin.pis.gov.pl/plikijednostki/ .../file/.../GiS_Raport_2013.pdf)

11.    Seńczuk W. Toksykologia Współczesna, PZWL, Warszawa, 2005

12.    Faber M.S., Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin. Pharmacol. Ther, 2004, 76(2),178-184.

13.    McKinnon R.A, Evans A.M. Cytochrome P450. Clinically Significant Drug Interactions. Aust. J Hosp Pharm., 2000, 30, 146.

14.    Ambrosone C.B. Freudenheim J.L. Graham S., Marshall J.R., Vena J.E., Brasure J.R., Laughlin R, Nemoto T., Michalek A.M., Harrington A. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res, 1995, 55(16), 3483-3485.

15.    Moon Y.J. Wang X., Morris M.E. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol. in Vitro. 2006, 20(2), 187-210.

16.     Stockley’s, Drug Interactions. A source book of interactions, their mechanisms, clinical importance and management. 2008, The Pharmaceutical Press, London, Eight Edition. Edited by Karen Baxter (www. stockley-drug-interaction-2008.pdf)

17.    Mayo P.R. Effect of passive smoking on theophylline clearance in children. The Drug Monit. 2001, 23(5), 503-505.

18.    Orzechowska-Juzwenko K. Farmakologia kliniczna. Znaczenie w praktyce medycznej, Górnicki Wydawnictwo Medyczne, Wrocław, 2006.

19.    Hukkanen J., Jakob P 3rd, Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005, 57(1), 79-115.

20.    Perkins K.A., Lerman C., Keenan J., Fonte C., Coddington S. Rate of nicotine onset from nicotine replacement therapy and acute responses in smokers. Nicotine Tob. Res. 2004, 6(3), 501-507.

21.    Kostka-Trąbka E., Woroń J. Interakcje leków w praktyce klinicznej. PZWL Warszawa  2011 (Wydanie II uaktualnione).

22.    Eldon M.A., Luecker P.W., MacGee J., Ritschel W.A. Lack of effect withdrawal from cigarette smoking on theophyline pharmacokinetics. J. Clin. Pharmacol., 1987, 27(3), 221-225.

23.    Gex-Fabry M., Balant-Gorgia A.E., Balant L.P. Therapeuting drug monitoring of olanzapine: the combined effect of age, gender, smoking and comedication. Ther. Drug Monit. 2003, 25(1), 46-53.

24.    Diaz F.J., de Leon J., Josiassen R.C., Cooper T.B., Simpson G.M. Plasma clozapine concentration coefficients of variation in long-term study. Schizophr Res. 2005, 72(2-3), 131-135.

25.    Ozdemir V., Kalow W.,  Posner P., Collins E.J., Kennedy J.L., Tang B.K., Albers L.J., Reist C., Roy R., Walkes W., Afra P. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patient with schizophrenia. J. Clin. Psychopharmacol, 2001, 21(4), 398-407.

26.    Haring C., Meise U., Humpel C, Saria A., Fleischhacker W.W., Hinterhuber H. Dose-related plasma levels of clozapine; influence of smoking, behaviour sex and age. Psychopharmacology. 1989, 99 (supl.), 38-40.

27.    Carrillo J.A., Herraiz A.G., Ramos S.I., Gervasini G., Vizcaino S., Benitez J. Role of smoking – induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady- state concentration of olanzepine. J. Clin. Psychopharmacol. 2003, 23(2), 119-27.

28.    B. Fulton, K.L. Goa, Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia  and related psychoses. Drugs, 1997, 53(2), 281-98.

29.    de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr. Serv. 2004, 55(5), 491-3.

30.    Nemeroff C.B., Kinkead B., Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions and dosing. J. Clin. Psychiatry. 2002, 63, 13, 5-11.

31.    Smoking and drug interactions 2007, Medicines Information Centre Pharmacy Department, UK Medicines Information, prepared by The Medicines Information Team, Pharmacy Department, Mersey Care NHS Trust (www.merseycare.nhs.uk/Library/.../Smoking_ Interactions.pdf)

32.    Schein J.R. Cigarette smoking and clinically significant drug interactions. Ann. Pharmacother. 1995, 29 (11), 1139-48.

33.    Wittkowsky A.K. Drug interactions update: drugs, herbs, and oral anticoagulation. J. Thromb. Thrombolysis. 2001,12(1), 67 –71.

34.    Himmelmann A., Jendle J., Mellen A., Petersen A.H., Dahl U.L., Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care, 2003, 26(3), 677-82.

35.     Wang. Z., Hall S.D., Maya J.F., Asghar A., Gorski J.C. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br. J. Clin. Pharmacol. 2003, 55, 77 - 85.

36.    Bol J., Mathijssen R.H.J., Loos W.J., Friberg LE., Schaik R.H.N., de Jonge MJ.A., Planting A.S.Th., Verweij J., Sparreboom A., de Jong F.A. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J. Clin. Onc. 2007, 25(19), 2719-26.

37.    Burkman R., Schlesselman J.J., Zieman M. Safety concerns and health benefits associated with oral contraception. Am. J. Obstet. Gynecol. 2004.190(4), S5-22.

38.     Seibert C., Barbouche E., Fagan J., Myint E., Wetterneck T., Wittemyer M. Prescribing oral contraceptives for women older than 35 years of age. Ann. Intern. Med. 2003;138(1):54-64.

39.    Schiff I., Bell W.R., Davis V., Kessler C.M., Meyers C., Nakajima S., Sexton B.J. Oral contraceptives and smoking, current considerations: recommendations of a consensus panel. Am. J. Obstet. Gynecol, 1999, 180(6), S383-384.

40.    World Health Organization. Low dose combined oral contraceptives. In: Medical eligibility criteria for contraceptive use. 3rd edition. Geneva (Switzerland). 7 World Health Organization; 2004., 1-24. (http://www.who.int/reproductive-health/ publications/ mec/mec.pdf.)

41.    Heinemann L.A., Assmann A., DoMinh T., Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational study on Oral Contraceptives and Health of Young Woman. Eur. J. Contracept Reprod. Health Care. 1999, 4(2), 67-73.

42.    Chalmers G.W., MacLeod K.J., Little S.A., Thomson L.J., McSharry C.P., Thomson N.C. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax, 2002, 57(3), 226-230.

43.    Chaudhuri R., Livingston E., McMahon A.D., Thomson L., Borland W., Thomson N.C. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am. J. Respir. Crit. Care Med. 2003, 168(11),1308-1311.

44.    Thomson N.C., Spears M. The influence of smoking on the treatment response in patients with asthma. Curr. Opin. Allergy Clin. Immunol. 2005, 5(1),57-63.

45.    Tomlinson J.E., McMahon A.D., Chaudhuri R., Thompson J.M., Wood S.F., Thomson N.C. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax, 2005, 60, 282-287.

46.    Etter J.F., Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction. 2011,106 (11), 2017-2028.

47.    Goniewicz M.Ł., Knysak J., Gawron M., Kosmider L.,. Sobczak A., Kurek J., Prokopowicz A., Jablonska-Czapla M.,. Rosik-Dulewska C, Havel Ch., Benowitz Jacop P., Benowitz N. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes, Tob. Control, 2013, 0, 1-7.

48.    Vardavas C.I., Anagnostopoulos N., Kougias M., Evangelopoulou V., Connolly G.N., Behrakis P.K. Short-term pulmonary effects of using an electronic cigarette. Chest. 2012, 141, 1400–1406. E-Cigarette Laws Worldwide. (www.ecigarette-politics.com/ electronic-cigarettes-global-legal-status.html)

49.    Dyrektywa Parlamentu Europejskiego i Rady 2014/40/UE z dnia 3 kwietnia 2014 r. w sprawie zbliżenia przepisów ustawowych, wykonawczych i administracyjnych państw członkowskich w sprawie produkcji, prezentowania i sprzedaży wyrobów  tytoniowych i powiązanych wyrobów oraz uchylająca dyrektywę 2001/37/WE (www.polbi.pl/pl/eurlex.spr?id=1705650)